Filing Details

Accession Number:
0001567619-19-019357
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-10-08 17:37:24
Reporting Period:
2019-10-07
Accepted Time:
2019-10-08 17:37:24
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1437402 Ardelyx Inc. ARDX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1611184 Mark Kaufmann C/O Ardelyx, Inc.
34175 Ardenwood Blvd, Suite 200
Fremont CA 94555
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-10-07 20,000 $0.54 161,418 No 4 M Direct
Common Stock Disposition 2019-10-07 20,000 $4.56 141,418 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2019-10-07 20,000 $0.00 20,000 $0.54
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
95,894 2021-08-11 No 4 M Direct
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 5, 2019.
  2. This transaction was executed in multiple trades in prices ranging from $4.50 to $4.64, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. Reflects the adjusted total which includes the purchase of 2,330 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2019
  4. The option is fully vested and exercisable.